<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928862</url>
  </required_header>
  <id_info>
    <org_study_id>000103</org_study_id>
    <nct_id>NCT01928862</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Prepopik™ in Children for Overall Colon Cleansing in Preparation for Colonoscopy</brief_title>
  <acronym>Prepopik PREA</acronym>
  <official_title>A Randomized, Assessor-Blind, Multicenter, Dose-Ranging Study Comparing the Safety and Efficacy of Prepopik™ Versus Polyethylene Glycol Preparation (Local Standard of Care) in Children Aged 9 Years to 16 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of Prepopik™ in children aged 9 to 16 years for overall
      colon cleansing in preparation of colonoscopy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects defined by &quot;excellent&quot; or &quot;good&quot; in the Aronchick Scale</measure>
    <time_frame>1 day of colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 33 days after colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal findings in laboratory tests</measure>
    <time_frame>Up to 7 days post colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal findings in physical exams</measure>
    <time_frame>From up to 21 days prior to colonoscopy and at the day of colonoscopy</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who took the assigned dose for colon cleansing</measure>
    <time_frame>approx. 1 day  (From the day before colonoscopy to the day of colonoscopy)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of each category of the &quot;Subject's Tolerability and Satisfaction Questionaire&quot;</measure>
    <time_frame>1 day of colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) assessment: Cmax (maximum concentration of drug in the blood)</measure>
    <time_frame>Up to 7 days after colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
    <description>For PK sampling 5 subjects per treatment group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: Tmax (time when maximum concentration of drug in the blood is achieved)</measure>
    <time_frame>Up to 7 days after colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
    <description>For PK sampling 5 subjects per treatment group will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK assessment: AUC (area under the curve correlates with the total amount of drug exposure in the blood)</measure>
    <time_frame>Up to 7 days after colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
    <description>For PK sampling approximately 5 subjects per treatment group will be assessed</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Need for Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>Prepopik™ ½ sachet (9-12 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prepopik™ ½ sachet (9-12 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prepopik™ 1 sachet (9-12 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prepopik™ 1 sachet (9-12 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral polyethylene glycol (PEG) based preparation (9-12 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prepopik™ 1 sachet (13-16 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prepopik™ 1 sachet (13-16 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral polyethylene glycol (PEG) based preparation (13-16 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prepopik™ ½ sachet (9-12 years)</intervention_name>
    <arm_group_label>Prepopik™ ½ sachet (9-12 years)</arm_group_label>
    <other_name>Prepopik™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prepopik™ 1 sachet (9-12 years)</intervention_name>
    <arm_group_label>Prepopik™ 1 sachet (9-12 years)</arm_group_label>
    <other_name>Prepopik™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral polyethylene glycol (PEG) based preparation (9-12 years)</intervention_name>
    <arm_group_label>Oral polyethylene glycol (PEG) based preparation (9-12 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prepopik™ 1 sachet (13-16 years)</intervention_name>
    <arm_group_label>Prepopik™ 1 sachet (13-16 years)</arm_group_label>
    <other_name>Prepopik™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral polyethylene glycol (PEG) based preparation (13-16 years)</intervention_name>
    <arm_group_label>Oral polyethylene glycol (PEG) based preparation (13-16 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 9 years to 16 years, inclusive, being scheduled to undergo
             elective colonoscopy

          -  Subjects must have had 3 or more spontaneous bowel movements per week for 1 month
             prior to the colonoscopy

          -  Female subjects of childbearing potential must undergo a pregnancy test at screening
             and again at randomization

        Exclusion Criteria:

          -  Acute surgical abdominal conditions (e.g., acute obstruction or perforation)

          -  Hospitalized  for inflammatory bowel disease

          -  Any prior colorectal surgery, excluding appendectomy, hemorrhoid surgery, or prior
             endoscopic surgical procedures

          -  Colon disease (history of colonic cancer, toxic megacolon, toxic colitis, idiopathic
             pseudo obstruction, hypomotility syndrome, colon resection)

          -  Ascites

          -  Gastrointestinal disorder (active ulcer, outlet obstruction, retention,
             gastroparesis, ileus)

          -  Upper gastrointestinal surgery (gastric resection, gastric banding, gastric bypass)

          -  Significant cardiovascular disease as determined by the investigator

          -  If subject has a history of renal insufficiency, serum creatinine and potassium must
             be within normal limits

          -  Any clinically significant laboratory value at screening, including pre- existing
             electrolyte abnormality, based on clinical history

          -  Hypersensitivity to active ingredients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IU Medical Center / Riley Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook Children's</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>August 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
